Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide 1 vs 5 Minute Delayed Release for Chronic Rhinosinusitis
NCT04476628Phase 1Withdrawn
- Sponsor
- St. Paul's Hospital
- Start
- Feb 2021
- Primary completion
- Jan 2022
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, randomised, single-blind trial of budesonide in chronic rhinosinusitis (CRS) (2 arms), sponsored by St. Paul's Hospital. Primary endpoints: Modified Lund Kennedy Score at 20 weeks and Sino-nasal Outcome Test-22 at 20 weeks. Planned start Feb 2021; status: withdrawn.
02
Drugs
budesonide
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NCT04476628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04476628.